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REAL-WORLD UTILIZATION PATTERN OF BIOLOGICS IN RHEUMATOID
ARTHRITIS: A POPULATION-BASED STUDY
Liao CH, Wang YC, Chen JJ, Pwu RF
Center for Drug Evaluation, Taipei, Taiwan
OBJECTIVES: In November 2011, Center for Drug Evaluation completed the project
which aimed to re-evaluate the currently reimbursed biologics for rheumatoid
arthritis (RA), and to establish the evidence-based revision rules of reimbursed
items covered by National Health Insurance (NHI). As part of the project, this study
analyzed the NHI claim data to capture the utilization and prescription pattern of
reimbursed biologics in adult patients.METHODS: Identity-encrypted claims data,
including inpatient, ambulatory care and contracted pharmacies prescriptions,
during 2001 to 2010 were utilized. All records with etanercept, adalimumab and
rituximabwere identified in the first step. Then the records were further separated
into RA and non-RA usage, according to the diagnosis codes. Moreover, the RA
patients who were newly treated with biologics were enrolled to assess long-term
prescription pattern.We performed both Kaplan-Meier analyses to assess biologics
switching over time and medication possession rates to evaluate medication
compliance. RESULTS: The expenditure of biologics for RA patients increased rap-
idly in the past decade and came to NT$ 1.37 billion in 2010. Among 5,142 patients
treated by biologics in 2010, 88% received etanercept or adalimumab, and 12%
received rituximab. In prescription pattern analysis, rituximab was not reported
due to lack of long-term data (reimbursed for RA since November 2008). A total of
3,928 and 1,508 patients initialed by etanercept and adalimumab were analyzed,
separately. About 34% of etanercept subjects appeared switching over 85 months
and 27% of adalimumab subjects applied second biologics over 45 months. The
mean durations of continuous prescription were 29 months and 14 months, and
the medication possession rates were 78% and 93%, respectively. CONCLUSIONS:
Under current reimbursement rules, the persistence and compliance of biologic for
RA patients were satisfactory. However, the increasing numbers of patients and
biological alternatives might intensify the financial pressure on NHI.
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DOES NATIONAL ESSENTIAL MEDICINE SYSTEM IMPROVE RATIONAL DRUG
USE IN PRIMARY HEALTH CARE FACILITIES? AN EMPIRICAL STUDY IN RURAL
CHINA
Song Y, Bian Y
University of Macau, Macau, Macau, China
OBJECTIVES: To examine the effect of National Essential Medicine System (NEMS)
on rational drug use (RDU) in primary health care facilities in rural China and to
provide reflections and policy implications for currently implemented new health
care reform. METHODS: Data was obtained from 151 township hospitals in four
provinces by means of field survey (stratified random sampling) conducted be-
tween 20102011. Indicators of RDU were compared before and after NEMS, and
discussed in regard to WHO Standard Guidelines or data from other researches.
RESULTS: Under NEMS, average number of drugs per encounter decreased from
3.64 to 3.46 (p0.01). Little effectwas found in the average number of antibiotics per
encounter, but the percentage of encounters with antibiotics prescribed decreased
from 60.26% to 58.48%(p0.01). The percentage of encounters with injection pre-
scribed and the percentage of encounters with hormone prescribed also decreased
and the current proportion was 40.31% and 11.16%, respectively. But unfortunately
all the above values remained higher than WHO international standards. The per-
centage of drugs prescribed from National Essential Drug List increased from
63.33% to 79.89% (p0.01). The average expenses per encounter increased from
RMB 25.77 to 26.71 with the available data, but was not significant (p0.362) and
warranted further investigation.CONCLUSIONS:The implementation of NEMShas
greatly improved rational drug use in primary health care facilities in rural China.
But the over-prescription of antibiotics and injections and polypharmacy remain
common. Treatment guidelines should be established and closely adhered to. Con-
tinuingmedical education on RDU for both healthworkers and the public aswell as
intensive support supervision are the essential actions taken.
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OFF-LABEL USE OF INTRAVENOUS NON-STEROIDAL ANTI-INFLAMMATORY
DRUGS-KETOROLAC IN A NATIONALLY REPRESENTATIVE POPULATION
Hsiao FY1, Gau CS2
1National Taiwan University, Taipei, Taiwan, 2Center for Drug Evaluation, Taipei, Taiwan
OBJECTIVES: Emerged evidence has linked non-steroidal anti-inflammatory drugs
(NSAIDs) to cardiovascular adverse outcomes. Specifically, parenteral NSAIDs such
as ketorolac were associated with higher risk of adverse outcomes than oral ones.
Recent policy concern has therefore focused on the rational use of parenteral
NSAIDs. Using 2000-2009 Taiwan’s National Health Insurance research database
(NHIRD), the objective of this study was to provide an estimate of off-label use of
ketorolac in a nationally representative sample.METHODS: Inpatient (n303,733)
and outpatient prescriptions (n605,750) of parenteral ketorolac from 2000
through 2009 were identified from a random sample of 1,000,000 individuals in
NHIRD in 2005. Ketorolac prescribing outside the indications approved by the Tai-
wan Food and Drug Administration (i.e. short term use ( 5 days) for postoperative
pain) was defined as off-label use. Differences in patient and prescriber character-
istics between licensed and off-label prescriptions were assessed with chi-square
tests for categorical variables and t-tests for continuous variables. RESULTS: Off-
label use of ketorolac was estimated to be 28.5% at the inpatient settings. The
off-label use was more frequent at the outpatient settings (90% of the outpatient
prescriptions), with the highest proportion of off-label use among pediatric pa-
tients (6 years old (y/o): 97.2%, 6-18 y/o: 95.8%, 18-65 y/o: 95.1%, and 65 y/o:
94.7%). Approximately 50% of the outpatient off-label prescriptions of ketorolac
came from metropolitan hospitals. Also, the majority of the outpatient off-label
prescriptions of ketorolac were prescribed by the emergency departments.
CONCLUSIONS: Our results suggest that the actual extent of off-label use of ke-
torolac could be very high, especially at the outpatient settings. It highlights the
need for a better understanding of the reasons behind this phenomenon, a more
appropriate definition of the role of ketorolac in pain managements, and a more
efficient policy intervention to rationalize the use of ketorolac.
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DOES COMBINATION PHARMACOLOGICAL INTERVENTION FOR SMOKING
CESSATION PREVENT POST-CESSATION WEIGHT GAIN?
Wang X1, Yang M2, Bhowmik D2, Abughosh S2
1Universtiy of Houston, Houston, TX, USA, 2University of Houston, Houston, TX, USA
OBJECTIVES: A systematic review was conducted to summarize if combination
pharmacological therapy for smoking cessation offers an effective way to reduce
post-cessation weight gain.METHODS: The following databases were researched:
Medline, Pubmed, PsycINFO, CENTRAL and EMBASE. Detailed inclusion and exclu-
sion criteria were specified a prioribefore conducting abstract and full text screen-
ing. Included studies were required to: 1) report data on combination pharmaco-
therapy including at least one FDA-approved smoking cessation medication; 2)
report outcome measure of weight change; 3) incorporate a minimum of 2-week
follow-up; and 4) recruit adult smokers. Studies were excluded if they had 1) be-
havioral interventions; 2) sample size of  30; 3) switching medications; or 4) they
were not written in English. Abstracts and the full texts were reviewed indepen-
dently by two investigators. Inclusion of studies was decided by a third indepen-
dent investigator in case of disagreement between the two primary investigators.
RESULTS:Out of 1873 citations identified, a total of 1083 citationswere included for
abstract screening. Finally 13 studies met the eligibility criteria after full text
screening of 242 citations. Seven studies showed that participants in the combined
therapy group had less post-cessation weight gain than those in the group of indi-
vidual drugs or placebo. Four studies did not report differential weight gain mea-
sures by treatment groups, another study only reported the results of F-tests
among treatment groups, and smoking cessation groups without reporting pre-
post average weight change. Only one study showed that post-treatment weight
gain in the combined therapy group was more than the monotherapy group, al-
though the result was not statistically significant. CONCLUSIONS: Seven out of
thirteen studies indicated that combination smoking cessation medications had
less post-cessation weight gain than monotherapy or placebo in short term. Long
termweight gain was not well documented bymost of the studies and is subjected
to future research.
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ASSESSMENT OF THE IN EXCESS NHI-COVERED MEDICATIONS OF
OUTPATIENTS IN A 2000-BED MEDICAL CENTER IN TAIWAN
Wu SC1, Yu IW2, Chen YL1, Lin HW1
1China Medical University, Taichung, Taiwan, 2China Medical University Hospital, Taichung,
Taiwan
OBJECTIVES: To evaluate the extent of excess NHI-covered medications in China
Medical University Hospital (CMUH), as the surrogate indicator of inappropriate
prescribing andmedication practices.METHODS: Those patients who have visited
outpatient units in CMUH 3 for 50% of all outpatient visits were assigned as CMUH
loyal patients by Bureau of NHI in Taiwan. They have received Integrated Medical
Care (IMC) services in CMUH since December 2009. Patients who have visited out-
patient units in CMUH, including those in IMC services, were encouraged to recycle
their excess prescription medications to the Department of Pharmacy and learn
about proper medication use and its disposal during July 2011 to February 2012.
Those retrieved prescription medications were classified based upon their clinical
applications and checked for their reimbursed cost using information obtained
from the Bureau of NHI. The differences during implementation period between
IMC service group and usual care (UC) group were compared using Chi-squaredtest
and t-tests. RESULTS: While 32 patients in IMC group and 15 in the UC group
recycled their excess medications, more patients in the IMC group had coronary
artery disease (p0.03). Although IMC group have made more outpatient visits
significantly thanUCgroup (2924 vs. 99, p 0.004), their inpatient visits in CMUH
were similar. The average pill counts were 433119 versus 22360 (p 0.03) and
cost of excess prescription medication were 2,219607 versus 2,126950 NTD in
IMC andUC group, respectively.While HTN, DMandhyperlipidemiawere the three
major diseases in both groups, those agents for cardiovascular disease and DM
accounted for 39% and 15% of all estimated cost of excess medication.
CONCLUSIONS:With the substantial excess, NHI-covered medications for chronic
illness among CMUH outpatients, it is necessary to come up with workable strat-
egies to enhance appropriate prescribing and medication use in outpatient units.
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MARKET ANALYSIS OF ANTIBIOTICS CONSUMPTION IN NORTHERN PART OF
IRAN DURING 2001-2010
Zaboli P1, Ala S2, Kebriaee Zadeh A1, Abdollahiasl A3, Nikfar S1
1Tehran University of Medical Sciences, Tehran, Tehran, Iran, 2Mazandaran University of
Medical Sciences, Sari, Mazandaran, Iran, 3Tehran University of Medical Sciences, Tehran, Iran
OBJECTIVES: Iran’s Rational Drug Use Committee (RUD) reported that antibiotics’
consumption rate has been arisen in the past decade and theywere among the first
five most used drugs. Irrational use of antibiotics can cause microbial resistance
and move a huge part of the government financial support, this research looks
forward to study about the antibiotic consumption’s in Northern stateswhich have
around 10% of the whole Iran’s population and comparing them with Iran’s total
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consumption to find any significant difference.METHODS:A total of 161 antibiotics
are in Iran’s drugs list. According to Iran’s FDO regulations all pharmaceutical
companies should report their sales statistics to this organization each month.
Sales amount could be derived from this database state by state. According toWHO
method, each drug ATC and DDD code have been derived. DID index (Defined daily
dose /1000 Inhabitants/ Day) have been calculated according to the population of
each states. RESULTS: Correlation coefficients of ascending trends of antibiotics in
Northern states’ and Iran have been reported respectively as following: In oral
antibiotics, four classes have significant ascending trend: Betalactams (0.715 vs.
0.693), Cephalosporines (0.99 vs. 0.989), Macrolides (0.911 vs. 0.949), Quinolones
(0.897 vs. 0.9). Three classes have significant descending trend: Amphenicoles
(-0.836 vs. -0.76), Sulfonamides (- 0.924 vs. -0.948), Aminoglycosides (-0.809 vs.
-0.943). In parenteral antibiotics two classes have significant ascending trend: Imi-
penem (0.967 vs. 0.979), Macrolides (0.951 vs. 0.95). Two of them have significant
descending trend: Betalactams (- 0.916 vs. -0.79), Aminoglycosides (-0.809 vs.
-0.943). CONCLUSIONS: Most trends were ascending and same as the pattern of
whole countries consumption. These results approve the theory of the priority in
training programs to clinicians and people according to RUD’s goals in Northern
states’ same as other parts of country.
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CONSUMPTION OF ANTIDIABETICS IN SERBIA IN 2010: A COMPARISON WITH
CROATIA AND DENMARK
Pavlovic´ N1, Stanimirov B1, Stojancˇevic´ M1, Paut Kusturica M1, Sabo A2, Tomic´ Z1, Mikov
M1
1University of Novi Sad, Medical Faculty, Novi Sad, Serbia and Montenegro, 2Faculty of Medicine,
University of Novi Sad, Novi Sad, Vojvodina, Serbia and Montenegro
OBJECTIVES: Considering diabetes as a major public health problem worldwide,
the aim of our study was to analyze overall volume of use of antidiabetics, com-
pared to Croatia, as the neighboring country, and Denmark, chosen for its rational
and conservative prescription practice. METHODS: Data for consumption of anti-
hyperglycaemic drugs (A10) in 2010 were obtained by a retrospective, observa-
tional, population-based study. Utilization of these drugs was expressed as DDD
per 1000 inhabitants a day (DID). RESULTS: In 2010, antidiabetics (A10) were used at
a similar rate in Serbia, Croatia and Denmark (47.34 DID, 49.88 DID and 47.50 DID,
respectively), but the share of utilization of insulins (A10A) and oral antidiabetics
(A10B) differed between countries. Relatively high proportion of insulin use in Den-
mark (36.2% of all antidiabetics) compared to Serbia (22.0%) and Croatia (26.4%)
may be attributed to high incidence of type 1 diabetes in Nordic countries and
compliance with most of recent pharmacotherapeutic guidelines that suggest the
use of long-acting insulins (A10AE) in type 2 diabetes (4.0 DID of A10AE inDenmark,
in comparison to 1.28 DID in Serbia and 1.91 DID in Croatia). Proportions of oral
antidiabetics use also differed between these countries. Metformin, as the only
biguanide (A10BA) used and preferred oral agent for type 2 diabetes, accounted for
51.2% of total use of oral antidiabetics in 2010 in Denmark, while sulfonylureas
(A10BB), as a second-line treatment, were used at a rate of 36.6%. In Serbia and
Croatia, sulfonylureas were used predominantly (55.6% and 48.6, respectively).
New medicinal products with effect on the incretin system (A10BH and A10BX)
were used at a rate of 4.1 DID in Denmark, contrary to 0.45 DID in Croatia and 0.002
DID in Serbia. CONCLUSIONS: The large differences in utilization of various an-
tidiabetics between observed countries suggest considerable variations in habits,
especially with regard to type 2 diabetes treatment.
PHP27
THE EFFECT OF RETIREMENT ON MENTAL HEALTH
Meng SH1, Lin W2, Chang RE1
1National Taiwan University, Taipei, Taiwan, 2Chang Jung Christian University, Tainan, Taiwan
OBJECTIVES: To explore the effect of retirement on retiree’s mental health, this
study investigated the change in the usage of sedative-hypnotic drugs after the
retirement for sedative-hypnotic users. METHODS: We conducted a retrospective
cohort study with comparison groups through following a population-based ran-
dom sample containing one-million beneficiaries of Taiwan’s National Health In-
surance from 1999 to 2009. Individuals retired between 2000 and 2003 and aged
between 50 and 64 were first identified. Those taking sedative-hypnotic drugs at
least one year before and six years after retirement were selected as the study
sample, and were further stratified into high-dosage and low-dosage users based
on their defined daily doses (DDDs). A propensity score (PS) matching was con-
ducted to select two non-retiree control groups with respect to sedative-hypnotic
dosage. Each non-retiree was assigned a pseudo retirement date, the same retire-
ment date as his/her matching retiree counterpart. Nonparametric Wilcoxon tests
were conducted to compare the differences in DDDs between the retiree and con-
trol groups. Generalized estimating equations (GEE) were employed to investigate
the odds ratios (ORs) of drug usage between the retiree and control groups.
RESULTS: 9,687 retired sedative-hypnotic users were identified. After PSmatching,
the number of high-dosage users in both retiree and control groups was 3,265, and
the number of low-dosage users was 3,072. The Wilcoxon tests revealed no differ-
ence in DDDs between the retirees and non-retirees before and after their retire-
ments. The GEE analyses however showed that, compared to their non-retiree
counterparts, the low-dosage retired users significantly reduced the dosage of after
their retirement (OR0.97, p  0.05). A similar trend was observed in the high-
dosage users but no significance. CONCLUSIONS: The decrease in the dependence
on sedative-hypnotic drugs after their retirements for low-dosage usersmight sug-
gest the retirement had a positive influence on mental health.
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SYSTEMATIC REVIEW ON FACTORS AFFECTING PHARMACEUTICAL
EXPENDITURES
Mousnad MA1, Shafie AA2, Mohamed Ibrahim MI3
1Universiti Sains Malaysia, Penang, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia,
3Qatar University, Doha, Qatar
OBJECTIVES: To systematically identify the main factors those contribute towards
the increase of pharmaceutical expenditures. METHODS: A systematic search of
published studies was conducted in common major electronic databases using
search terms “factors’’, ‘‘financing ’’, ‘‘pharmaceutical’’, and ‘‘expenditures’’. To be
included the studies need to 1) measure at least one of the following outcomes:
total growth in pharmaceutical expenditures, price growth quantity growth; 2) A
clear method to analyze the impact of factors affecting the increases of drug ex-
penditures was mentioned; 3) were written in English. Non-primary articles that
were published only as abstract, review; commentary and letter were excluded.
Data were extracted from the primary eligible studies using data abstraction form.
Information regarding study title, study author (s), country, year, study objective,
study design, statisticalmethods to assess factors affecting pharmaceutical expen-
ditures, results, and author (s) conclusionswere collected.RESULTS: Froma total of
2039 studies, only 20 studies were included for full review. The most significant
determinants or factors of drug spending are demographic, disease category, pub-
lic health, price, utilization, therapeutic choice, and residual –productmix. A num-
ber of studies from the review indicate that residual –product mix responsible for
between approximately 30 per cent to approximately 493 per cent of total increases
drug expenditures. CONCLUSIONS: Price change has little effect on expenditure
increases compared with utilization and the residual. All the above factors need to
be considered for optimum drug policy design. It is most important for policy
makers to understand pharmaceutical spending trends, the factor influencing the
rising of the limited resources and the main cost containment strategies.
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CONSIDERABLE DIFFERENCES IN THE UTILIZATION OF ANTIDEPRESSANTS
BETWEEN SERBIA AND DENMARK
Stojancˇevic´ M1, Paut kusturica M1, Stanimirov B1, Pavlovic´ N1, Sabo A2, Tomic´ Z1, Mikov
M1
1University of Novi Sad, Medical Faculty, Novi Sad, Serbia and Montenegro, 2Faculty of Medicine,
University of Novi Sad, Novi Sad, Vojvodina, Serbia and Montenegro
OBJECTIVES:Depressive disorder is one of themajor public health problems due to
significant disability that it causes, aswell difficulties in diagnostic procedures. The
aim of the study was to determine the total antidepressant utilization in Serbia in
correlation with Denmark and to get insight into financial resources allocations.
Denmark was chosen for its developed pharmacotherapeutic practice.METHODS:
Data for antidepressant (ATC group N06) utilization and consumption of financial
resources in 2010 were retrieved from the annual reports of relevent public insti-
tutions. The ATC/DDD methodology was applied and results were expressed in
defined daily doses (DDDs) per 1000 inhabitants per day (DID). RESULTS: An inter-
esting result of our study is that the utilization of antidepressants in 2010 appeared
to be 7-fold higher in Denmark (83.8 DID) than in our country (11.67 DID). In accor-
dancewith these results, the consumption of financial resources for groupN06was
approximately 9-fold higher inDenmark (89.680.072USD) than in Serbia (10.261.963
USD). The most commonly used group of antidepressants in both countries were
selective serotonine reuptake inhibitors (SSRI) (67.3% and 73.76% of all antidepres-
sants for Denmark and Serbia respectively) which complies with the most recent
clinical guidelines. There was a considerable difference between Denmark and
Serbia in the utilization of a group N06AX which includes new generation of anti-
depressants (22.7 DID and 1.39 DID respectively). CONCLUSIONS: The differences
between selected countries in antidepressant utilization and consumption of fi-
nancial resources are partly consequential to different socioeconomic and health
policy factors. This study shows that the overall utilization of antidepressants in
Serbia is lower than in Denmark, which implies possible underdiagnosing of affec-
tive disorders in general practice.
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THE UTILIZATION AND EXPENDITURE OF REIMBURSED DIGESTIVE ENZYME
AGENTS IN TAIWAN
Yang WW, Wang YC, Pwu RF
Center for Drug Evaluation, Taipei, Taiwan
OBJECTIVES: To analyze the current utilization and expenditure of reimbursed
digestive enzyme agents (DEs) in Taiwan. METHODS: The encrypted claim data-
base of National Health Insurance (NHI) was used to analyze the prescription pat-
terns and the expenditure of DEs for types of diseases, health care specialties,
levels of medical institution, and insured BNHI branch. RESULTS: We identified
that 29DEs,within 15 groupings, are reimbursed byNHI up to 2011. Given thatmost
DEs were developed in earlier stage, while only 2 items were approved by the
Taiwan Food and Drug Administration after 2000, these approved items had
broader scope of approved indications and limited evidence on their clinical effi-
cacy. According to the analysis of 2001-2010 NHI databases, the most enzymes
prescribed disease was gastroenteritis, related uncomfortable symptoms, and so
forth. Over the ten years, the number of medical orders increased from 22.77 mil-
lion to 46.71 million. Medical costs increased from more than NT$ 1 hundred mil-
lion to over NT$ 2 hundred million. The highest usage rate of medical orders, by
specialties, is 64% in Internal Medicine, especially in Gastroenterology and in Gen-
eral Medicine. The second is 7% to 9.6 % in Family Medicine. The usage rate is
increasing each year in Surgery, from 4.13% in 2011 to 9.27% in 2010. The usage
rates of medical order by 15 groupings have various trends of levels between dif-
ferent medical institution, and different insured BNHI branch. CONCLUSIONS:
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